Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Elysium Therapeutics

Elysium Therapeutics
2013 FOUNDED
PRIVATE STATUS
Angel LATEST DEAL TYPE
$215K LATEST DEAL AMOUNT
3 INVESTORS
Description

Developer of opioid pain relievers intended to protect individuals from oral misuse, abuse and fatal overdose. The company's opioid pain medications automatically prevent the opioid levels in the bloodstream from exceeding certain parameters and also minimize addiction and side effects, enabling medical practitioners to enhance the ability of pain patients and employ effective opioid-based pain management systems.

Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • 9000 Crow Canyon Road
  • Suite 620
  • Danville, CA 94506
  • United States

+1 (925) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Elysium Therapeutics’s full profile, request a free trial.

Elysium Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Angel (individual) 21-Mar-2019 $215K 00.00 Completed Product Development
6. Seed Round 07-Sep-2018 00000 00.000 Completed Product Development
5. Grant 01-Jan-2018 00000 00000 Completed Product Development
4. Angel (individual) 20-Dec-2017 00000 00000 Completed Product Development
3. Grant 01-Jan-2017 00.000 Completed Startup
2. Grant 01-Jan-2015 $3.04M Completed Startup
1. Grant 01-Jan-2014 $442K Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Elysium Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Mid Atlantic Bio Angels Angel Group Minority 000 0000 000000 0
Ohio Third Frontier Corporation 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0

Elysium Therapeutics Executive Team (2)

Name Title Board
Seat
Contact
Info
Gregory Sturmer Co-Founder, Chief Executive Officer, President & Board Member
Thomas Jenkins Ph.D Co-Founder, Chief Scientific Officer & Board Member

Elysium Therapeutics Board Members (5)

Name Representing Role Since Contact
Info
Bob Rappaport MD Self Board Member 000 0000
Gregory Sturmer Elysium Therapeutics Co-Founder, Chief Executive Officer, President & Board Member 000 0000
James Hackworth Ph.D Self Board Member 000 0000
Kathleen LaPorte Self Board Member 000 0000
Thomas Jenkins Ph.D Elysium Therapeutics Co-Founder, Chief Scientific Officer & Board Member 000 0000